Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor

Teagle, 2014, Management of pyoderma gangrenosum, J. R. Soc. Med., 107, 228, 10.1177/0141076814534407 Marzano, 2017, Autoinflammation in pyoderma gangrenosum and its syndromic form(pyoderma gangrenosum) acne and suppurative hidradenitis), Br. J. Dermatol., 176, 228, 10.1111/bjd.15226 Maverakis, 2018, Diagnostic criteria of ulcerative pyoderma gangrenosum: a delphi consensus of international experts, JAMA Dermatol, 154, 461, 10.1001/jamadermatol.2017.5980 Alavi, 2017, Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment, Am. J. Clin. Dermatol., 18, 355, 10.1007/s40257-017-0251-7 McKenzie, 2019, Biologic and small-molecule medications in the management of pyoderma gangrenosum, J. Dermatol. Treat., 30, 264, 10.1080/09546634.2018.1506083 Cinats, 2018, Janus kinase inhibitors: a review of their emerging applications in dermatology, Skin Therapy Lett, 23, 5 Scheinberg, 2020, Steroid-resistant sarcoidosis treated with baricitinib, Ann. Rheum. Dis., 10.1136/annrheumdis-2020-217271 Ahn, 2018, Pyoderma gangrenosum: a review of pathogenesis and treatment, Expet Rev. Clin. Immunol., 14, 225, 10.1080/1744666X.2018.1438269 Montagnon, 2020, Pyoderma Gangrenosum in hematological malignancies, J. Am. Acad. Dermatol., 82, 1346, 10.1016/j.jaad.2019.09.032 Kridrin, 2021, Rheumatoid arhtirtis and pyoderma gangrenosum : a population-based case control study, Clin. Rheumatol., 40, 521, 10.1007/s10067-020-05253-7